Why Analysts Are Positive on Vertex Pharmaceuticals Incorporated (VRTX)'s Story

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is among the most profitable healthcare stocks to buy. On January 26, UBS increased the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $545 from $535 and reiterated a Buy rating on the stock. According to TheFly, the firm is optimistic about the U.S. Pharmaceuticals and Biotechnology group, primarily due to attractive valuations, favorable positioning, and sustained pharma-led M&A initiatives.

Earlier, on January 23, Evercore ISI lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $530 from $475 and maintained an Outperform rating. This follows the firm’s updated analysis of the Vertex model, with revisions focused on povetacicept’s pricing and total addressable market (TAM), as well as changing views of the BAFF/APRIL environment.

Interestingly, povetacicept is expected to nearly double the current high consensus forecast of $4 billion, with substantial upside not yet fully realized by investors. That said, the firm remains confident in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s pipeline, particularly the revenue potential of its BAFF/APRIL inhibitor program in the long haul.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a Massachusetts-based biotechnology company specializing in therapies for treating cystic fibrosis (CF). Founded in 1989, the company is committed to bringing transformative medicines to patients with life-threatening diseases.

While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.